National Pension Service Has $90.35 Million Stock Holdings in Edwards Lifesciences Corporation $EW

National Pension Service increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 998,775 shares of the medical research company’s stock after acquiring an additional 7,009 shares during the period. National Pension Service owned about 0.17% of Edwards Lifesciences worth $90,349,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Cidel Asset Management Inc. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $227,000. Plimoth Trust Co. LLC bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $206,000. Pinnacle Wealth Management Advisory Group LLC raised its position in Edwards Lifesciences by 5.9% during the second quarter. Pinnacle Wealth Management Advisory Group LLC now owns 4,018 shares of the medical research company’s stock valued at $363,000 after acquiring an additional 224 shares in the last quarter. NorthRock Partners LLC lifted its stake in Edwards Lifesciences by 1.0% in the second quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock valued at $1,465,000 after acquiring an additional 153 shares during the last quarter. Finally, Squarepoint Ops LLC grew its position in Edwards Lifesciences by 51.2% in the second quarter. Squarepoint Ops LLC now owns 27,261 shares of the medical research company’s stock worth $2,466,000 after acquiring an additional 9,235 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Edwards Lifesciences Stock Performance

EW opened at $84.54 on Friday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock’s 50 day moving average price is $89.16 and its two-hundred day moving average price is $85.79. The firm has a market capitalization of $48.68 billion, a P/E ratio of 48.59, a price-to-earnings-growth ratio of 2.28 and a beta of 0.85. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This represents a 12.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,664 shares of company stock worth $511,918 in the last ninety days. 0.31% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on EW shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Mizuho increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Citigroup increased their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.